Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 15/20 | 0.51 |
| ▸ | PPARD | Q03181 | 11/20 | 0.51 |
| ▸ | PPARG | P37231 | 11/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.43 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13433354 | 0.83 | SYK (0.45) | PPARAPPARDPPARGEPHX2ITGA4 | |
| SCHEMBL3418629 | 0.82 | PPARA (0.45) | PPARAPPARDPPARGITGA4ITGB7 | |
| SCHEMBL3416367 | 0.81 | PPARG (0.44) | PPARAPPARDPPARGITGA4ITGB7 | |
| SCHEMBL13433343 | 0.77 | FDPS (0.47) | PPARAPPARDPPARG | |
| SCHEMBL3419255 | 0.77 | TRPV1 (0.48) | PPARAPPARDPPARGITGA4ITGB7 | |
| SCHEMBL3415307 | 0.76 | PPARD (0.63) | PPARAPPARDPPARGEPHX2 | |
| SCHEMBL3416346 | 0.76 | PPARG (0.53) | PPARAPPARDPPARG | |
| SCHEMBL13433348 | 0.76 | EPHX2 (0.48) | PPARAPPARDPPARGEPHX2ITGA4 | |
| SCHEMBL3413605 | 0.76 | PPARG (0.45) | PPARAPPARDPPARGITGA4ITGB7 | |
| SCHEMBL6496923 | 0.76 | PPARA (0.45) | PPARAPPARDPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687664-B2 | Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-7687664-B2 | Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20040214888-A1 | Carboxylic acid derivative and medicine comprising salt or ester of the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-10-28 | — | — | US | disclosed |
| EP-1394147-A1 | CARBOXYLIC ACID DERIVATIVE AND MEDICINE COMPRISING SALT OR ESTER OF THE SAME | Eisai Co., Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214888-A1 | Carboxylic acid derivative and medicine comprising salt or ester of the same | GPR119, NR3C1, INSR | PPARA 130/4885PPARD 689/4885PPARG 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.